A pancreatic cancer vaccine shows promise in immune testing, but the randomized trial did not meet its primary disease-free survival endpoint. The study did not establish an overall survival benefit, so the results do not show that camupepimut extends life or prevents cancer from returning.
The phase 2 AMPLIFY-7P trial enrolled 144 people with KRAS-mutated pancreatic cancer at stages 1 to 3. All participants had undergone surgery and chemotherapy before joining. Imaging showed no recurrence when they entered the trial. Researchers assigned 96 participants to receive the vaccine and 48 to an observation control group.
Vaccine Shows Promise in Immune Response
Researchers developed camupepimut to target several common KRAS mutations. The source describes it as an “off-the-shelf” treatment that could potentially work across people with different KRAS mutations. Unlike personalized vaccines designed around an individual tumor, this approach was developed to address mutations shared by multiple patients.
The vaccine delivers its components to lymph nodes, where immune cells can learn to recognize cancer cells with KRAS mutations. It activated mutation-targeting T cells in nearly 99% of the vaccine group. T-cell activity increased by more than ninefold in 82.2% of participants evaluated for that measure.
Those immune findings did not translate into a statistically significant disease-free survival result. Median disease-free survival was 23.8 months in the vaccine group, compared with 21.2 months in the observation group. At six months, 75.7% of vaccine recipients and 61.7% of controls remained disease-free. The early difference did not reach statistical significance, and the researchers found no significant improvement across the full follow-up period.
The reported trial results therefore show immune activation without a demonstrated survival benefit. A strong immune response is a biological measure; it does not by itself prove that patients live longer or remain cancer-free. The trial’s primary survival endpoint was not met.
Exploratory Findings Need Confirmation
Researchers conducted additional analyses to explore whether some participants might respond differently. People with no detectable circulating tumor DNA, or ctDNA, at the trial’s start appeared to have better disease-free survival after vaccination. The team also observed an association between stronger T-cell responses and longer disease-free survival.
These findings are exploratory. They do not show that the vaccine is effective for people without detectable ctDNA, nor do they establish that a stronger T-cell response caused longer disease-free survival. Larger studies would need to test those possibilities. The source explains that detectable ctDNA can indicate cancer cells remain after treatment.
Researchers reported that the vaccine was generally well tolerated, with no treatment-related deaths or adverse events that caused participants to stop treatment.
The work is part of a broader research effort to study cancer treatments and diagnostics. Meditech Wire has covered a separate cancer treatment avenue involving gamma delta T cells, as well as a lung cancer diagnostic collaboration. Those reports concern different research and do not provide evidence about camupepimut.
The next planned step for camupepimut is a phase 3 trial. Researchers may consider additional booster doses and combinations with other treatments, according to the source. Anton Bilchik, who was not involved, called the findings important despite the lack of a statistically significant survival benefit. He said the study’s small size and limited vaccination period may have influenced results.
Jason Williams, also not involved, said immune activation is only part of the challenge. He described recognizing cancer as one step and clearing it as another, and said a larger randomized trial would need to show patients stay cancer-free longer. The planned phase 3 study will need to determine whether the immune response produces a measurable clinical benefit.
Meditech Wire has also reported on support for cancer research through the Jimmy Fund Walk. That separate story offers context on research support, not an additional result from this vaccine trial.
